Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Anemo Labs has raised £700,000 in pre-seed funding to develop its AI-driven technology for detecting disease-related compounds through smell, led by Zinc and SFC Capital.
London-based deeptech startup Anemo Labs has raised £700,000 in pre-seed funding. The company is focused on developing an electronic nose for non-invasive disease screening through smell. The funding will support the advancement of its technology, which combines sensor hardware with AI models. Anemo Labs aims to identify signs of disease before symptoms appear.
Company Information
Company
Anemo Labs
Location
Greater London, England, United Kingdom
About
Anemo Labs is a deeptech startup focused on developing technology for disease detection through smell. Founded in 2025, the company is creating an electronic nose that combines sensor hardware with AI models to detect volatile organic compounds. Their initial application is in healthcare, utilizing non-invasive methods to analyze VOCs from urine for early disease identification. The company's objective is to help clinicians and individuals identify diseases before symptoms appear.
Don't miss Anemo Labs's next move
Get an email the moment Anemo Labs raises, hires an exec, or expands, usually minutes after it happens.
Greater LondonBiotechnologyHealth CareArtificial IntelligenceHealth Diagnostics